FcRn: Same Class, Different Paths—Spot Agent Differentiators
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Turning Flares Into Function: Flag Uncontrolled Disease
When to Begin FcRn: Initiation Criteria, Key Evidence
The 2-Point Signal: Apply ≥2-Point Rule
Shared Goals, Shared Gains: Align With Patient Preferences
ENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive Years
Linda Bradley, MD
Obianuju Sandra Madueke-Laveaux, MD, MPH
Lauren R. Kornegay
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): Overcoming Diagnostic and Therapeutic Challenges
Karin J. Blakemore, MD
Emilie L. Vander Haar
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Lee P. Shulman, MD, FACMG, FACOG
Samantha Denäe
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
James A. Simon, MD, CCD, NCMP, IF, FACOG
Pre- and Postoperative Use of GnRH Antagonists
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
Strategies to Address Healthcare Disparities in Patients With Endometriosis
Melissa Simon, MD
Why Are the Fetus and Placenta Not Rejected by the Mother? New Insights Into Maternal Anti-Fetal Rejection
Roberto Romero, MD, DMedSci
Alloimmune Neutropenia of the Fetus and Newborn
Masja de Haas, MD, PhD
Alloimmune Thrombocytopenia in the Fetus and Newborn
James B. Bussel, MD
Loading...
We're glad to see you're enjoying Omnia Education… but how about a more personalized experience?
Press cancel to remain on Omnia Education. Press the link below or the continue button to keep going.